Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER)
Sachin Kheterpal(University of Michigan), Leif Saager(Outcomes Research Consortium), Douglas A. Colquhoun(University of Michigan), Patrick J. McCormick(Memorial Sloan Kettering Cancer Center), Karsten Bartels(School of the Art Institute of Chicago), Michelle T. Vaughn(University of Michigan), Lori D. Bash(School of the Art Institute of Chicago), Nirav Shah(University of Michigan), Timur Dubovoy(School of the Art Institute of Chicago), Roy G. Soto(Oakland University), Robert B. Schonberger(Yale University), Michael R. Mathis(School of the Art Institute of Chicago), Amit Bardia(Harvard University), Amy Shanks(School of the Art Institute of Chicago)
Cited by 302
Related Papers
Risk Implications of the New CKD Epidemiology Collaboration (CKD-EPI) Equation Compared With the MDRD Study Equation for Estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study
|American Journal of Kidney Diseases|2010|311
Change in Estimated GFR Associates with Coronary Heart Disease and Mortality
|Journal of the American Society of Nephrology|2009|276
Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy
|Archives of Internal Medicine|2008|186
Chromosome 1q21.2 and additional loci influence risk of spontaneous coronary artery dissection and myocardial infarction
|Nature Communications|2020|98